JP2008512394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512394A5 JP2008512394A5 JP2007530543A JP2007530543A JP2008512394A5 JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5 JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- epha4
- antagonist
- receptor
- rnai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000021727 EphA4 Receptor Human genes 0.000 claims 16
- 108010055179 EphA4 Receptor Proteins 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 108091030071 RNAI Proteins 0.000 claims 8
- 230000009368 gene silencing by RNA Effects 0.000 claims 8
- 206010018341 Gliosis Diseases 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000050554 Eph Family Receptors Human genes 0.000 claims 5
- 108091008815 Eph receptors Proteins 0.000 claims 5
- 229940122293 Ephrin antagonist Drugs 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000007387 gliosis Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 230000003376 axonal effect Effects 0.000 claims 3
- 206010061431 Glial scar Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905148A AU2004905148A0 (en) | 2004-09-08 | A method of treatment and agents useful for same | |
| AU2004905148 | 2004-09-08 | ||
| US64796805P | 2005-01-27 | 2005-01-27 | |
| US60/647,968 | 2005-01-27 | ||
| PCT/AU2005/001363 WO2006026820A1 (en) | 2004-09-08 | 2005-09-08 | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Division JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512394A JP2008512394A (ja) | 2008-04-24 |
| JP2008512394A5 true JP2008512394A5 (https=) | 2008-10-09 |
| JP5094395B2 JP5094395B2 (ja) | 2012-12-12 |
Family
ID=36036018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080254023A1 (https=) |
| EP (1) | EP1793854A4 (https=) |
| JP (2) | JP5094395B2 (https=) |
| CA (1) | CA2579352A1 (https=) |
| NZ (1) | NZ553273A (https=) |
| WO (1) | WO2006026820A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| CA2579352A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
| JP2009543801A (ja) * | 2006-07-13 | 2009-12-10 | ノバルティス アクチエンゲゼルシャフト | 神経障害処置におけるトリフルオロメチル置換ベンズアミドの使用 |
| JP5580598B2 (ja) | 2007-11-15 | 2014-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | γ−セクレターゼの新規基質ＥｐｈＡ７を利用したスクリーニング方法 |
| US7892769B2 (en) * | 2007-11-30 | 2011-02-22 | Eisai R&D Management Co., Ltd. | Processing of EphA4 polypeptide by γ-secretase activity |
| EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| JP6059017B2 (ja) | 2010-12-17 | 2017-01-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法 |
| JP5961608B2 (ja) | 2011-04-25 | 2016-08-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| JP6847824B2 (ja) * | 2014-07-15 | 2021-03-31 | サンフォード バーナム プレビーズ メディカル ディスカバリー インスティテュート | 神経保護および神経修復用のｅｐｈａ４環状ペプチドアンタゴニスト |
| RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
| AR119303A1 (es) | 2019-07-01 | 2021-12-09 | Eisai R&D Man Co Ltd | Anticuerpo anti-epha4 humano |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) * | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| ATE293989T1 (de) * | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
| AU2003268345A1 (en) * | 2002-09-24 | 2004-04-19 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| WO2004041197A2 (en) * | 2002-11-01 | 2004-05-21 | Case Western Reserve University | Methods of inhibiting glial scar formation |
| WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
| CA2579352A1 (en) * | 2004-09-08 | 2006-03-16 | The University Of Queensland | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
-
2005
- 2005-09-08 CA CA002579352A patent/CA2579352A1/en not_active Abandoned
- 2005-09-08 NZ NZ553273A patent/NZ553273A/en not_active IP Right Cessation
- 2005-09-08 WO PCT/AU2005/001363 patent/WO2006026820A1/en not_active Ceased
- 2005-09-08 US US11/662,355 patent/US20080254023A1/en not_active Abandoned
- 2005-09-08 EP EP05778955A patent/EP1793854A4/en not_active Withdrawn
- 2005-09-08 JP JP2007530543A patent/JP5094395B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-15 JP JP2012030227A patent/JP2012136529A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Knoll et al. | Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats | |
| Million et al. | CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats | |
| Arborelius et al. | Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation | |
| Daenen et al. | Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus | |
| JP2008512394A5 (https=) | ||
| Beamer et al. | N w‐Propyl‐l‐arginine (L‐NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses | |
| Brait et al. | Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome | |
| Ebbinghaus et al. | The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses | |
| Desai et al. | A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors | |
| Feng et al. | Activation of guanylate cyclase-C attenuates stretch responses and sensitization of mouse colorectal afferents | |
| Zychowska et al. | Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target–evidence from a mouse diabetic neuropathy model | |
| Abraham et al. | β1-and β2-adrenoceptor induced synaptic facilitation in rat basolateral amygdala | |
| LeBlanc et al. | Plasma dopamine and noradrenaline variations in response to stress | |
| Ibrahim et al. | Docetaxel reverses pulmonary vascular remodeling by decreasing autophagy and resolves right ventricular fibrosis | |
| Yamaoka et al. | Different analgesic effects of adenosine between postoperative and neuropathic pain | |
| Seyer et al. | Cannula implantation into the lateral ventricle does not adversely affect recognition or spatial working memory | |
| RU2008116567A (ru) | Биомаркеры | |
| Jacobsen et al. | Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan | |
| Banks et al. | Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy | |
| McGaraughty et al. | Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats | |
| Oluyomi et al. | α‐Adrenoceptor Involvement in Swim Stress‐induced Antinociception in the Mouse | |
| Zhang et al. | Involvement of galanin receptor 2 and CaMKII in galanin-induced antinociception in periaqueductal grey of rats | |
| Bitar et al. | Spinal cord noradrenergic dynamics in diabetic and hypercortisolaemic states | |
| Park et al. | Short-term cold exposure may cause a local decrease of neuropeptide Y in the rat hypothalamus | |
| Ma et al. | CART peptides increase 5-hydroxytryptamine in the dorsal raphe and nucleus accumbens of freely behaving rats |